Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 2Q

Worldwide pharmaceutical sales were $5.5 billion in the quarter (-13%), including a 5% negative impact from currency.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 2Q

2Q Revenues: $15.2 billion (-7%)

2Q Earnings: $3.2 billion (-4%)

YTD Revenues: $30.3 billion (-7%)

YTD Earnings: $6.7 billion (-3%)

Comments: Worldwide pharmaceutical sales were $5.5 billion in the quarter (-13%), including a 5% negative impact from currency. Domestic sales were down 16% and international sales were down 9%, the latter of which reflected an operational increase of 3% but a negative currency impact of 12%. Remicade sales were $1.1 billion (+24%). Sales of Prezista were $140 million (+59%). Velcade sales were $229 million (+12%) and Concerta sales were $317 million (+14%). Sales of Topamax and Risperdal were down 73% and 66%, respectively, due to generic competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters